Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 215

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin

Ljunggren, Ö., Bolinder, J., Johansson, L., Wilding, J., Langkilde, A. M., Sjöström, C. D., Sugg, J., Parikh, S.·2012·Diabetes, Obesity and Metabolism

Abstract

Aims: Dapagliflozin, a selective sodium‐glucose cotransporter 2 ( SGLT2 ) inhibitor, reduces hyperglycaemia in patients with type 2 diabetes ( T2DM ) by increasing urinary glucose excretion. Owing to its mechanism of action, dapagliflozin could potentially affect the renal tubular transportation of bone minerals. Therefore, markers of bone formation and resorption and bone mineral density ( BMD ) were evaluated in patients with T2DM after 50 weeks of dapagliflozin treatment. Methods: This international, multi‐centre, randomized, parallel‐group, double‐blind, placebo‐controlled study ( ClinicalTrials.gov NCT00855166 ) enrolled patients with T2DM (women 55–75 years and men 30–75 years; HbA1c 6.5–8.5%; BMI ≥ 25 kg/m 2 ; body weight ≤ 120 kg) whose T2DM was inadequately controlled on metformin. One hundred and eighty‐two patients were randomly assigned 1:1 to receive dapagliflozin 10 mg/day or placebo added to open‐label metformin for a 24‐week double‐blind treatment period followed by a 78‐week site‐ and patient‐blinded extension period. At week 50, serum markers of bone formation (procollagen type 1 N‐terminal propeptide; P1NP ) and resorption (C‐terminal cross‐linking telopeptides of type I collagen; CTX ), bone mineral density ( BMD ) as assessed by standardized Dual‐Energy X‐ray Absorptiometry ( DXA ) measurements and adverse events of fracture were evaluated as safety objectives. Results: One hundred and sixty‐five patients (90.7%) completed the first 50 weeks. Compared with placebo, no significant changes from baseline in P1NP , CTX or BMD were identified over 50 weeks of dapagliflozin treatment, with no significant treatment‐by‐gender interactions. No fractures were reported. Conclusions: Dapagliflozin had no effect on markers of bone formation and resorption or BMD after 50 weeks of treatment in both male and post‐menopausal female patients whose T2DM was inadequately controlled on metformin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2012.01630.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 215

Metadata

Authors
Ljunggren, Ö., Bolinder, J., Johansson, L., Wilding, J., Langkilde, A. M., Sjöström, C. D., Sugg, J., & Parikh, S.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2012-06-29
Volume
14
Issue
11
Pages
990-999
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2080383778
Cited by
215
References
3
FWCI
13.58
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. https://app.cochat.ai/papers/10.1111/j.1463-1326.2012.01630.x
The paper
Ljunggren, Ö., Bolinder, J., Johansson, L., Wilding, J., Langkilde, A. M., Sjöström, C. D., Sugg, J., & Parikh, S. (2012). Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2012.01630.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.